SEA Deal Ticker
Singapore's Biobot Surgical raises $15.5M led by ClavystBio to enter the US market
The surgical-robotics firm raised S$20M from Temasek-backed ClavystBio and ZIG Ventures to scale its Mona Lisa prostate-cancer platform, which has deployed 80-plus systems and treated over 30,000 patients across Europe and Asia.
Positive-sum angle: A homegrown medtech exporting precision prostate diagnostics from Singapore into the US inverts the usual flow — proof that SEA deep-tech can sell hardware into the world's most demanding clinical market.